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The nucleotide sequence of the VP1 (1D) and partial 3D 
polymerase (3D
pol) coding regions of the foot and mouth 
disease  virus  (FMDV)  vaccine  strain  A/Iran87,  a  highly 
passaged  isolate  (∼150  passages),  was  determined  and 
aligned  with  previously  published  FMDV  serotype  A 
sequences. Overall analysis of the amino acid substitutions 
revealed that the partial 3D
pol coding region contained four 
amino acid alterations. Amino acid sequence comparison of 
the VP1 coding region of the field isolates revealed deletions 
in  the  highly  passaged  Iranian  isolate  (A/Iran87).  The 
prominent G-H loop of the FMDV VP1 protein contains the 
conserved arginine-glycine-aspartic acid (RGD) tripeptide, 
which  is  a  well-known  ligand  for  a  specific  cell  surface 
i n t e g r i n .  D e s p i t e  l o s i n g  t h e  R G D  s e q u e n c e  o f  t h e  V P 1  
protein  and  an  Asp26→Glu  substitution  in  a  beta  sheet 
located within a small groove of the 3D
pol protein, the virus 
grew in BHK 21 suspension cell cultures. Since this strain 
has been used as a vaccine strain, it may be inferred that the 
RGD deletion has no critical role in virus attachment to the 
cell during the initiation of infection. It is probable that this 
FMDV  subtype  can  utilize  other  pathways  for  cell 
attachment.
Keywords: 3D
pol protein, deletion, RGD, VP1 protein
Introduction
Foot and mouth disease (FMD) is an economically 
important disease of cloven-hoofed livestock such as 
cattle, sheep, and other domestic animals in addition to 
several wild-life species. The causative agent of the FMD 
is the foot and mouth disease virus (FMDV) [9,11,18]. The 
disease is considered one of the most important barriers to 
the worldwide trade of livestock and animal products [12]. 
FMDV isolates sampled from the world have been 
categorized into seven different serotypes, A, O, C, Asia1, 
and South African Territories 1 (SAT1), SAT2, and SAT3, 
according to antigenic levels; and a large number of 
variants have appeared within each serotype. Out of the 
three serotypes (O, A, and Asia1) found to be prevalent in 
Iran in recent years, serotype A has been found to be more 
antigenically and genetically diverse than the others 
[6,10,14].
The FMDV possesses a single-stranded RNA molecule 
consisting of about 8,200 nucleotides within an 
icosahedral capsid composed of structural proteins [12]. 
The open reading frame encodes a single polyprotein 
which can be cleaved into four structural proteins (VP4, 
VP2, VP3, and VP1) and eight non-structural proteins (L, 
2A, 2B, 2C, 3A, 3B, 3C, and 3D polymerase [3D
pol]). In 
general, structural proteins are more variable than non- 
structural proteins. Mutations or deletions in structural 
proteins may help the FMDV to evade immune responses 
of the host whereas mutations or deletions in non-structural 
proteins can inhibit viral replication and protein processing 
[5].
The FMDV usually infects cells by binding to integrin 
receptors via a long flexible loop (G-H loop) of VP1 (1D). 
The sequence of this loop contains a conserved arginine- 
glycine-aspartic acid (RGD) tripeptide motif which is 
characteristic of ligands that bind to integrin receptors 
[16]. The VP1 protein is encoded by the VP1 coding region 
of viral RNA; this coding region is 627∼639 bp long and 
produces a protein containing 209∼213 amino acid 
residues depending on the serotype [6]. The 3D
pol gene 
sequence is 1,410 nucleotides in length. This gene contains 
a TAA stop codon and is responsible for encoding a protein 
containing 470 amino acid residues [4]. Similar to other 
picornaviruses, the FMDV 3D
pol protein is a viral-encoded 
RNA polymerase. Among the different FMDV serotypes 
and subtypes, both the nucleotide and amino acid 364    Majid Esmaelizad et al.
sequences of 3D
pol are highly conserved [14]. Uninterrupted 
co-circulation of the virus in the environment and the 
absence of viral polymerase proofreading activity during 
the replication process lead to the appearance of various 
genetic isolates [2]. Analysis of the viral genome sequence 
is a crucially important approach for monitoring field 
isolates in areas where the disease is endemic.
Previous studies have shown that Iran has one of the 
highest reported rates of FMD cases per year [17]. In Iran, 
FMD is largely controlled by vaccinating cattle and sheep 
with vaccines prepared against isolates that are likely to be 
encountered in the region. Spread of the disease is 
promoted by the presence of large populations of 
susceptible animals, low vaccination rates, prevalence of 
multiple serotypes (including serotypes A, Asia1, and O), 
and unlimited movement of susceptible animals in the 
country. Furthermore, there is endemic co-circulation of 
multiple genotypes of type A virus [19]. The high 
incidence of FMD has allowed the identification of new 
variants of the virus over the last 7 years [17]. The general 
objective of this study was to determine the nucleotide 
sequences of genes encoding VP1 and 3D
pol proteins of a 
type A FMDV (A/Iran87) highly adapted to cell culturing, 
and to compare them to other corresponding sequences 
available in the GenBank database.
Materials and Methods
The Razi Vaccine and Serum Research Institute (Iran) 
generously provided samples of the FMDV used for our 
study. Clinical specimens of FMDV which included 
samples in tongue epithelium tissue were collected in 1987 
from infected calves displaying clinical symptoms of FMD 
in an Iranian field located in Tehran. The A/Iran87 strain 
was initially detected and isolated nearly more than two 
decades ago. Thus, the highly passaged virus investigated 
in this study was not virus isolated from the field. The 
tissue samples were used to infect baby hamster kidney 21 
(BHK-21) cells. The virulent isolate was passaged in BA 
(cell line derived from pig kidney) and BHK-21 cell 
monolayers. Propagation steps included six passages in 
BA cells and then four passages in BHK-21 cells. 
Thereafter, it has been used for the development of FMD 
vaccines during the past years as a vaccine seed. The 
infected cell culture supernatant from the ∼150th passage 
was clarified and stored at 򰠏70
oC before use.
RNA extraction and reverse transcription-polymerase 
chain reaction (RT-PCR)
Total RNA was extracted from FMDV-infected BHK-21 
cells using an RNX plus kit (Cinnagen, Iran) according to 
the manufacturer’s instructions. Briefly, the cell culture 
was centrifuged at 85,000× g at 4
oC for 2 h. The pellet was 
resuspended in 200 μL of PBS, mixed well with 400 μL of 
RNX reagent, and incubated at room temperature for 5 
min. RNA was extracted with 0.2 μL chloroform : 
isoamylalcohol (24 : 1). RNA in the aqueous solution was 
precipitated by adding an equal volume of isopropanol. 
The mixture was then centrifuged at 10,000 × g for 20 min. 
The pellet was washed with 75% ethanol and dissolved in 
20 μL of RNase-free water. 
RT-PCR was carried out in 50 μL of reaction mixture 
containing 10 μL of 5× reaction buffer, 4 μL of mixed 
dNTPs (2.5 mM each), 1 μL of AMV enzyme (Titan One 
Tube RT-PCR system kit; Roche Diagnostic, Germany), 1 
μL of each primer (10 pmol each), 4 μL of RNA template, 
2.5 μL DTT, 3 μL 25mM MgCl2, and 23.5 μL of H2O. The 
following conditions were used for amplification: 42
oC for 
30 min, 94
oC for 3 min; 30 cycles of 94
oC for 30 sec, 52
oC 
for 30 sec, 72
oC for 40 sec; then followed by 72
oC for 5 
min. The VP1 and 3D
pol coding regions of FMDV (621 and 
690 bp, respectively) were amplified using standard 
methods with a one-step RT-PCR system and specific 
primer combinations. Primers sequences were as follows: 
forward: 3FMG6 5´-ctctggtaccatcaacctgcac-3´ and reverse: 
Nk61 5´-gacatgtcctggtgcatctg-3´ for 3D
pol, and forward: 
FMG13 5´-accaggatgatgattggcag-3´ and reverse: FM15 
5´-tttcactcctacggtgtcgc-3´ for VP1. Amplified PCR products 
of the expected length were separated by electrophoresis in 
a 1% agarose gel, stained with ethidium bromide, and 
visualized under a UV transilluminator.
Cloning of the PCR product, DNA sequencing, and 
sequence analysis
After successful amplification of the target DNA 
sequences, fragments were purified using a gel extraction 
kit (Roche, Germany) following the recommendations of 
the supplier. Ligation was performed with plasmid vector 
pTZ57R/T (Fermentas, Germany) in 0.165 μg, 0.18 pmol 
ends and 0.54 pmol ends purified PCR fragment in 1× 
ligation buffer, polyethylene glycol (PEG 4000), 5 units of 
T4 DNA ligase, and up to 30 μL of deionized water at 22
oC 
for 16 h. The ligated products were used to transform 
chemically competent cells (XL1-Blue cells) and white 
colonies grown on LB plates were randomly selected. The 
cloned PCR products were purified using plasmid 
purification kit (Roche Diagnostics, Germany) according 
to the manufacturer’s instructions and sequencing was 
carried out in both directions using a T7 promoter primer 
(MWG Biotech, Germany).
The published sequences of 66 FMDV type A isolates 
recovered from different parts of the world were included 
in this analysis and compared to the corresponding sequence 
of the A/Iran87 isolate. Reference FMDV sequences were 
obtained from the National Center for Biotechnology 
Information (NCBI, USA). The sequences used for each 
gene were first examined to exclude ambiguous sequences 
which were incomplete or frame-shifted. To determine the Molecular characterization of amino acid deletions in VP1 (1D) protein    365
Fig. 1. Alignment of the translated amino acid sequences of the (A) VP1 and (B) 3D polymerase (3D
pol) genes. Dashes (򰠏) represent 
absent amino acids. Differences in amino acids among the isolates are indicated by a single letter code. Red boxes indicate amino acid
deletions and substitutions in the consensus sequence (A/Iran87) relative to the other isolates.366    Majid Esmaelizad et al.
Table 1. Description of type A field isolates used to determine the sequence variability in the protein VP1 and 3D polymerase coding 
regions
Serial no. Isolate Location Date of collection Accession No.
　1 a10holland iso82 Netherlands 1942 AY593751
　2 a12valle 119 iso20 United Kingdom 1932 AY593752
　3 a15thailand iso43 Thailand 1960 AY593755
　4 a29peru iso37 Peru 1969 AY593773
　5 a14 spain iso39 Spain 1959 AY593754
　6 a2spain iso7 Spain 1969 AY593774
　7 a32ven iso36 Venezuela 1970 AY593775
　8 a18zulia iso40 Venezuela 1967 AY593758
　9 a1bayern iso41 Germany 1971 AY593759
10 a21kenya iso77 Kenya 1964 AY593761
11 A-SAU-41-91 Saudi Arabia 1991 FJ755085
12 a16belem iso80 Brazil 1959 AY593756
13 a13brazil iso75 Brazil 1958 AY593753
14 abage iso63 Brazil 1977 AY593787
15 aparma iso55 Italy 1962 AY593792
16 a23kenya iso8 Kenya 1965 AY593766
17 a27columbia iso78 Colombia 1967 AY593771
18 a5allier iso45 France 1960 AY593780
19 a4wg iso72 Germany 1972 AY593779
20 a5westerwald iso73 Germany 1951 AY593781
21 A30 Uruguay-68 iso90 Uruguay 1968 AY593801
22 A uruguay 2001 iso98 Uruguay 2001 AY593802
23 aphilippines iso50 Philippines 1975 AY593793
24 a argentina 2000 iso104 Argentina 2000 AY593782
25 aarg2001 iso93 Argentina 2001 AY593783
26 a25 argentina iso38 Argentina 1959 AY593769
27 acanefa iso48 Argentina 1961 AY593789
28 a general lopez iso102 Argentina 2001 AY593790
29 Talasskiy Kazakhstan 1999 FJ623456
30 A-VN-03-2009 Viet Nam 2009 GQ406249
31 A-VN-20-2009 Viet Nam 2009 GQ406252
32 PAK1 Pakistan 2006 EF494487
33 PAK5-2006 Pakistan 2006 EF494488
34 Lindholm 1.3,PAK3-2006 Pakistan 2006 EF117837
35 A-AFG-7-2007 Afghanistan 2007 FJ755008
36 A-Igdir-TUR-382-06-99 Turkey 1999 DQ296550
37 A-Kayseri-TUR-1263-11-00 Turkey 2000 DQ296544
38 A-TUR-5-2003 Turkey 2003 FJ755093
39 a22turkey iso66 Turkey 1965 AY593765
40 AIRN2005_WRL Turkey 2005 EF494486
41 a28 Turkey iso44 Turkey 1972 AY593772
42 IND81-00 India 2000 HM854021
43 IND17-77 India 1977 HM854022
44 A22-India-17-77 India 1977 AF204108
45 IND243-04 India 2004 FJ617245
46 A-Iran87 Iran 1987 AY248743
47 airan iso105 Iran 1998 AY593791Molecular characterization of amino acid deletions in VP1 (1D) protein    367
Table 1. Continued
Serial no. Isolate Location Date of collection Accession No.
48 A/Iran87 Iran Vaccine AY370770
49 A Iran02 Iran 2002 DQ767858
50 A Iran04 Iran Vaccine DQ767860
51 A Iran06 Iran 2006 DQ767862
52 A-IRN-2-87 Iran 1987 EF208770
53 A-IRN-22-99 Iran 1999 EF208772
54 A22ir Iran Unknown EF405980
55 A87ir Iran 1987 EF405981
56 A-IRN-34-2001 Iran 2001 EU414526
57 A-Iran-vaccinal Iran Unknown AY898962
58 A-IRN-32-2001 Iran 2001 FJ755017
59 A-IRN-5-2003 Iran 2003 FJ755018
60 A-IRN-9-2003 Iran 2003 FJ755019
61 A-IRN-33-2004 Iran 2004 FJ755022
62 A/IRQ/24/2002 Iraq 2002 FJ755071
63 A-IRQ-33-2002 Iraq 2002 FJ755072
64 a22iraq64 iso86 Iraq 1964 AY593763
65 a22iraq70 iso92 Iraq 1970 AY593764
66 A-IRQ-24-2002 Iraq 2002 FJ755071
degree to which genetic diversity was observed in the VP1 
and 3D
pol proteins, multiple alignments and comparisons 
of the predicted amino acid sequences of isolates were 
carried out (Fig. 1). Nucleotide sequence homology/ 
divergence was calculated using the MegAlign project of 
the DNAStar software package (ver 5.1; DNAStar, USA; 
data not shown). The histories of the type A FMDV field 
isolates, including year of isolation, accession number, and 
geographical distribution, are presented in Table 1. The 
nucleotide sequences of the VP1 and 3D
pol coding regions 
of A/Iran87 have been submitted to GenBank (accession 
No. AY370770 and AY248743, respectively).
Results
Genetic comparison of the field isolates to the vaccine 
strain is of significant importance for testing the usefulness 
of the existing vaccine strain as well as selecting new 
vaccine strain(s). During virus circulation, amino acid 
substitutions accumulate at the different positions of the 
protein sequence. In the present study, a highly passaged 
field isolate of FMDV (A/Iran87) named Mardabad or A87 
isolate was selected for genetic analysis. Sequences of the 
protein coding regions (VP1 and 3D
pol) from the high- 
passage cell-adapted vaccine strain were determined by 
PCR amplification and sequencing. Comparison of the 
amino acid sequences revealed amino acid changes in both 
structural and non-structural proteins. The number of 
sequence differences exhibited by each of the isolates 
showed that A/Iran87 contains four amino acid 
substitutions at positions 17, 26, 50, and 57 in the 3D
pol 
coding region (Fig. 1). There is clear evidence of novel 
amino acid substitutions (Ala→Ser, Asp→Glu, Glu→
Asn, and Ala→Gly) in two domains of the 3D
pol protein. 
Comparison of the VP1 protein among different variants 
showed that A-Iran-vaccinal contained a change at 
position 179. At this position, Ala was replaced with Val. 
Fig. 1A shows that amino acid changes among the VP1 
genes of the field isolates consist of numerous nucleotide 
substitutions and deletions compared to the consensus 
sequence. Comparison of the predicted amino acid 
sequences of VP1 region in the field isolates revealed 
amino acid deletions in three Iranian vaccine isolates 
(A-Iran-vaccinal, A Iran04, and A/Iran87). As shown in 
Fig. 1A, deletions occurred within the 13 amino acid 
positions (168 to 180) of the VP1 region. Three- 
dimensional analysis of 3D
pol protein showed that the Asp
→Glu substitution occurred in a beta sheet located in a 
small groove of the protein.
The variations were not distributed uniformly along the 
genes; there were areas of high and low incidence of 
nucleotide sequence variation (data not shown). The 
region of the VP1 gene between amino acids 157 and 183 
contained a high degree of variation and encoded an 
important immunogenic site on the viral surface. 
Consequently, nucleotide changes in this region are most 
likely involved in the appearance of new antigenic 
variants. The VP1 and 3D
pol nucleotide sequences of the 368    Majid Esmaelizad et al.
Fig. 2. Phylogenetic tree showing relationships among different A field viruses according to the (A) VP1 and (B) 3D
pol gene sequences.
Lineages and bootstrap values are shown on the tree.
selected FMDV-A subtypes isolated from outbreaks in Iran 
and other countries were used to construct a FMDV-A VP1 
and 3D
pol-based sequence similarity tree. Fig. 2 shows a 
phylogenetic tree that was constructed based on the 
sequence alignment of 35 genomes of the VP1 region and 
42 genomes in the 3D
pol region which are distinctly divided 
into different lineages. As depicted in Fig. 2A, the 
A/Iran87 isolate clustered with a Saudi Arabian and five 
Iranian isolates into a branch separate from other type A 
isolates.
Fig. 2B demonstrates that A/Iran87 and all isolates 
examined in the present study originated from different 
geographical areas and did not cluster in relatively similar 
lineages based on 3D
pol sequences. All the field isolates 
shared comparatively lower homology (90∼93%) with 
the A/Iran87 isolate in the 3D
pol coding region (data not 
shown). The topology of the phylogenetic tree indicated 
that there was no remarkable similarity between A/Iran87 
and all other isolates in the 3D
pol coding region. Space- 
filling and worm styles of the three-dimensional structures 
of the 3D
pol and VP1 proteins from the A/Iran87 isolate 
were observed. Analysis of the 3D
pol protein structure 
showed that the Asp→Glu substitution occurred in a beta 
sheet located within a small groove of the protein. In order 
to examine the long amino acid deletion in the three- 
dimensional structure of the VP1 protein, homology-based 
modeling of the protein domains was carried out (Fig. 3). It 
indicated that, 13 amino acid deletions in the VP1 protein 
of A/Iran87 isolate caused a change in three-dimensional 
structure of protein in the G-H loop region.
Discussion
Detailed knowledge of the molecular characteristics of 
the major FMDV immunogenic components would be 
useful for monitoring various processes like evolution, 
genetic diversity, and virus origin, and for developing 
protective vaccines. Among the FMDV serotypes, 
serotype A has been found to include the greatest number 
of recently developed variants. Extreme genetic heterogeneity 
is largely due to the absence of viral polymerase 
proofreading activity [2]. FMDV variants also appear 
during continuous infection of animals on farms or 
proliferation in cell cultures. Furthermore, genetic 
diversification among FMDV subtypes can be caused by 
events occurring during recombination.Molecular characterization of amino acid deletions in VP1 (1D) protein    369
Fig. 3. (A) The predicted three-dimensional space-filling and 
worm style structures of the 3D
pol protein of the A/Iran87 isolate.
Novel amino acid substitutions are marked in yellow. (B) The 
predicted three-dimensional VP1 structure of the A/Iran87 
isolate determined by homology-based modeling. The arrow 
indicates 13-amino acid deletions including the arginine- 
glycine-aspartic acid (RGD) sequence in the G-H loop.
Along with above mechanisms, there is continuous 
co-circulation of multiple genotypes of FMDV type A 
which may lead to recombination; this progresses 
gradually between closely related isolates when multiple 
viral genotypes co-infect the host. Exchange of different 
genomic regions between FMDVs by recombination is 
directly linked to FMDV diversification. Recombination, 
particularly in the structural protein-coding region, may 
offer selective advantages to the virus. This can be great 
concern to areas where multiple FMDV genotypes 
co-circulate [19]. The presence of extensive antigenic 
variation among different FMDV isolates can hinder 
vaccination against FMDV [1,13].
Genetic polymorphisms amongst different type A 
subtypes demonstrated that four nucleotides in the 3D
pol 
coding region of isolate A/Iran87 (49, 78, 148, and 170) 
were changed from G to T, C to A, G to A, and C to G, 
respectively, resulting in amino acid substitutions Ala17→
Ser, Asp26→Glu, Glu50→Asn, and Ala57→Gly, respectively. 
In contrast to the A/Iran87 isolate, the remaining 41 
isolates showed no corresponding changes at these 
positions. Analysis of the sequence data revealed that the 
A/Iran87 isolate also contained 30 nucleotide deletions in 
region 501∼540 of the VP1 nucleotide sequence, which 
led to long amino acid deletions (RGDLGSLAARVAA) in 
the G-H loop. It should be noted that the RGD sequence 
was deleted from the G-H loop. The three-dimensional and 
antigenic structures of many different serotypes of the 
FMDV have been examined [8]. In spite of losing the RGD 
sequence and acquiring a Asp26→Glu substitution in a beta 
sheet located in a small groove of the 3D
pol protein, the 
virus grew in a BHK-21 suspension cell culture and 
exerted cytopathic effects after 16∼18 h. Since this strain 
is used as a vaccine strain, it may be inferred that the RGD 
does not have a key role in the virus binding to cells during 
infection. This virus subtype can probably use other 
pathways for cell attachment. As RGD sequence was 
found to be deleted, such a natural deletion in VP1 gene of 
FMDV is a novel phenomenon and has not been previously 
reported in compared isolates.
The VP1 capsid protein contains a mobile loop between 
the βG and βH strands on the virus surface; this protein not 
only contains the major immunodominant epitopes of the 
virion but also a highly conserved RGD amino acid 
sequence motif. RGD participates in binding FMDV to 
susceptible cells. Several studies using different approaches 
have indicated that naturally developed FMDV isolates 
attach to cells via the highly conserved RGD motif. 
FMDVs have been shown to use multiple RGD-dependent 
integrins of the αv subgroup to initiate infection; these 
include αvβ3, αvβ6, αvβ1, and αvβ8. On the other hand, 
these viruses are capable of entering cells via non-integrin 
pathways. Tissue culture-adapted FMDVs are able to utilize 
heparan sulfate (a glycosaminoglycan found on the cell 
surface) as a receptor for entering the cells. It has recently 
been found that FMDV can utilize unknown receptors 
except for integrin and heparan sulfate. This indicates the 
presence of other receptors and possible alternative 
mechanisms for viral particle entrance into the cells. This 
conclusion is also supported by the finding that destruction 
of the βG-βH loop RGD motif by site-directed 
mutagenesis created viruses which were able to replicate 
and assemble, but were not capable of initiating further 
infection cycles because of their inability to interact with 
cell receptors [18].
Previous findings from studies of synthetic peptides 
suggested that the carboxy-terminus of the VP1 protein 
situated in the vicinity of the RGD motif is required for 
RGD-mediated cell binding [3]. The G-H loop of the VP1 
protein on the viral particle surface is considered to be the 
dominant epitope for several FMDV types and the most 
variable part of the particle. Antibody-based responses 
against the loop have the ability to neutralize FMDVs in 
vitro and are protective in vivo. For example, replacing the 
whole or partial G-H loop leads to the doubling of antibody 
titers against type A virus. New findings in this field are in 
complete agreement with a previous report documenting 
that the only mutation which did not increase heterologous 
responses was deletion of the RGD-motif (3A) [8]. In 
another study, the RGD sequence was deleted from a 
genetically engineered FMDV (Type A12), thereby 370    Majid Esmaelizad et al.
rendering the virus particles incapable of binding to cell 
surfaces. Protective immunity in cattle has been obtained 
by utilizing particles from which the receptor binding site 
was deleted as a vaccine, revealing that this deletion has no 
significant effect on the antigenic properties of viruses 
with the RGD sequence [15].
Many reports [21] have suggested that FMDV subtypes 
can be obtained in the field by immune selection during 
outbreaks of FMDV which have not been effectively 
neutralized in animal populations with incomplete 
immunization. Thus, key changes in protein sequences that 
give rise to differences in immunogenicity and virulence 
can be seen among viruses isolated from partially 
immunized animals. In addition, it is possible that other 
significant changes take place when the virus moves from 
one host cell type to another. For instance, this may occur 
when FMDV spreads from one species to another (from 
cattle to swine and then back to cattle) or when FMDV 
cultured in BHK cells infects animal herds. For a number 
of years, it has been observed that FMDV easily adapts to 
many different tissue culture cell types. A recent report on 
a single passage of subtype A12 (AVR1) in BHK cells 
showed that some viral variants selected from this passage 
contained amino acid changes at residues 148 and 153 of 
the VP1, including ones that have a limited capability for 
eliciting cross-neutralizing antibodies [21].
The rapid generation of immunogenically distinguishable 
variants among FMDV subtype A viruses may affect the 
large-scale production of vaccines in BHK cells. 
Adaptation for growth in tissue culture can be used to 
select viruses that have antigenic and cell attachment 
site(s) different from those of the parental virus. Amino 
acid residues 134∼158 form a βG-βH loop structure 
which contains the main FMDV immunogenic epitope. In 
FMDV type C, mutation of residues 138∼140 and 148∼
150 in the VP1 region has been shown to affect FMDV 
antigenicity. Mutation frequency in the VP1 gene sequence 
of the FMDV has been estimated to be 1.6 × 10
򰠏3∼6.4 × 
10
򰠏3 substitutions for each nucleotide per year [6]. G-H 
loop-specific antibody responses are known to play a 
major role in immunity induced by the current FMDV 
vaccines. Considering the high sequence variability of this 
loop within and among the serotypes, it will be valuable to 
direct immune responses against other protective epitopes 
that are not as variable. Residues 140∼160 of VP1 have 
been previously shown to induce neutralizing antibodies 
against FMDV types O and A [20]. Due to a novel deletion 
of the 13 amino acid region including the RGD motif in the 
VPI capsid protein of A/Iran87, the effect of this motif in 
receptor binding and cell infection must be determined.
The FMDV-3D protein is a viral-encoded RNA 
polymerase. This protein was initially called the FMDV 
infection-associated antigen since antibodies to this 
antigen are be detected in serum from recovery animals 
[22]. The 3D
pol position is located at the C-terminus of the 
polypeptide next to the 3C gene product. The 3D
pol coding 
region produces a 470-amino acid protein with a molecular 
weight of ∼55 kDa. The pivotal role of 3D
pol in the viral 
replication process is attributed to the fact that the 3D
pol 
gene is highly conserved, particularly in the functional 
motifs. Since RNA polymerase is necessary for viral 
replication, the degree of sequence identity among the 
3D
pol genes is much greater than that of VP1 gene 
sequences [4].
A wealth of three-dimensional structural information is 
currently available for a large number of RNA-dependent 
RNA polymerases from different families of positive- and 
double-stranded RNA viruses, including three different 
members of the Picornaviridae family [7]. Considering the 
fact that this strain can infect BHK-21 cells and has been 
used as a vaccine strain for nearly two decades, it may be 
concluded that deletion of RGD has no critical role in virus 
binding to cells during the initiation of infection. It is 
probable that this FMDV subtype can utilize other 
pathways for cell binding. The findings of the current study 
demonstrated that the cell-adapted vaccine strain A/Iran87 
containing 13-amino acid deletions in the VP1 protein can 
be considered as a novel variant of FMDV type-A. This 
variant serves as a potent vaccine strain in Iran.
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